Pick a time period -
No more available filters You need to apply a filter before selecting newsroom

Use our filters to get your customized news. Save and subscribe to as many filters as you want, get the news that YOU are interested in right in your mailbox, RSS feed or in your personalized dashboard. Share your stories, news, multimedia and pressreleases and get a wider audience with news.cision.com.

Dicot AB presents Interim report Q2 2023

Press release: Uppsala, Sweden, August 24, 2023. Dicot AB (publ) publishes the interim report for the period January-June 2023. The report is available as an attached document and on the company's website www.dicot.se. Below is a summary of the report.Second quarter, April-June 2023 · Net sales amounts to KSEK 0 (0) · Earnings after financial items amounts to KSEK -10,050 (-8,733) · Earnings per share amounts to SEK -0.02 (-0.08) ”Dicot is entering a new era”, says Elin Trampe, CEO, as Dicot now enters the clinical phase with LIB-01. Significant events during the quarter

Lars Sandlund appointed as new CSO at XMReality

Starting in October, Lars Sandlund will join XMReality as Chief Sales Officer (CSO). Lars has most recently held the position of CEO at Dataton AB, a company that provides software and media servers to the professional audiovisual industry across the world.XMReality, a leading provider of remote visual assistance solutions powered by Augmented Reality, has recruited Lars Sandlund as Chief Sales Officer, CSO. Lars will take over the position from Andreas Jonsson, who transitioned to the role of XMReality’s CEO in May. Starting in October, Lars will lead XMReality’s sales activities with the

Interim report, January - June 2023

In Q2 2023 net sales increased by 23% compared to Q2 2022. Consolidated net sales ended at 74,820 (SEK 000s). EBITDA totaled to -17,615 (SEK 000s). Operating profit, EBIT, was -39,743 (SEK 000s). Profit after tax was -39,799 (SEK 000s). Earnings per share was SEK -0.59. For 1H 2023 net sales increased by 22% compared to 1H 2022. Consolidated net sales ended at 153,558 (SEK 000s). EBITDA totaled to -29,895 (SEK 000s). Operating profit, EBIT, was -73,937 (SEK 000s). Profit after tax was -83,307 (SEK 000s). Earnings per share was SEK -1.23.CEO's comments The heavy investments are setting

Last day of trading with the unit rights in Veg of Lund

Today, on 24 August 2023, is the last day of trading with the unit rights that were issued in connection to Veg of Lund AB’s (publ) (“Veg of Lund” or the “Company”) rights issue of units consisting of shares, which was announced on 4 August 2023 (the “Rights Issue”). Unit rights that are not sold or not exercised for subscription will expire worthless.NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, HONG KONG, JAPAN, CANADA, NEW ZEALAND, SWITZERLAND, SINGAPORE, SOUTH AFRICA, SOUTH KOREA, RUSSIA, BELARUS OR

Interim Report 230401-230630

Press Release, August 24, 2023 Revenue and Result Scandinavian Real Heart is working with research and development and currently has no sales of any products. The income reported for the period consists mainly of foreign currenty exhance gains. Research and development costs of Realheart® TAH were capitalized during Q2 with 3.5 MSEK. 1.2 MSEK for purchased services and other external costs and 2.3 MSEK for personnel. During the period, write-downs of capitalized costs for research and development were made by 0 MSEK. The item other external costs of 2.9 MSEK consists of

BoMill Q2 Report April – June 2023

BoMill AB (”BoMill” or the “Company”) hereby publishes the Interim Report for the period April 1 – June 30, 2023. The Interim Report is available as an attached file to this release and on BoMill’s website. Below is a summary of the report.Successful first installations of BoMill InSight™ paves way for commercial expansion CEO Andreas Jeppsson comments: “Another important milestone reached for BoMill, during this second quarter 2023, with the first two commercial installations of BoMill InSight™.“ Net sales and income for the second quarter (April – June 2023)           · Net

Annexin presents at ProHearings on August 29

Annexin Pharmaceuticals AB today announced that the company is participating at ProHearings’ Capital Markets Day on August 29, 2023, at 09:10 CET. CEO Anders Haegerstrand will present the latest development of the company, including the recently presented promising signals of effect in the company’s ongoing clinical RVO-study. The presentation and moderated Q&A session is broadcasted live via organizer’s website www.prohearings.com, where registration for in-person attendance at the venue in central Stockholm also is available. The presentation will also be available at Annexin’s website

Crunchfish publishes half-year report for 2023

Today, Crunchfish AB (“Crunchfish”) publishes the company’s half-year report for the second quarter and first six months 2023. Below is a brief summary of the report.Group financials 2023-04-01 2022-04-01 2023-01-01 2022-01-01 2023-06-30   2022-06-30  2023-06-30  2022-06-30         Net sales (SEK)  294,731  134,437  465,303  350,786Profit or loss  -8,639,245  -6,748,539  -15,467,604  -13,481,376before tax (SEK)Earnings per  -0.26  -0.22  -0.47  -0.44

XNK Therapeutics enters into research collaboration with Karolinska University Hospital in acute myeloid leukemia (AML)

XNK Therapeutics AB (“XNK”) today announced that the company has entered into a research collaboration with the Karolinska University Hospital, Sweden, to evaluate the suitability of the company’s autologous natural killer (NK) cell therapy candidate XNK02 as a novel therapy for treatment of acute myeloid leukemia (AML).In collaboration with Karolinska University Hospital, XNK will perform a large-scale bioreactor culture study of AML patients’ immune cells. These cells will be activated and expanded using XNK’s proprietary technology. The study aims to further investigate the expansion

Loyal Solutions announces second half year results for 1/1-30/06 2023

Danish SaaS company Loyal Solutions delivers 51% revenue growth in the second half year (1/1-30/6 2023)  and a 70% growth in ARR ( annual recurring revenue) for the year.CEO Peter Kisbye comments: “In the period 1 July 2022 – 30 June 2023 (“the Period”) the Company delivered the following results: · Growth in annual recurring revenue (ARR) of 70% · Top line revenue growth of 47%, reaching 98% of adjusted budget · Top line revenue growth of 51% in the second half of the year (1/1-30/6 2023) · EBITDA of TDKK -14,359 vs adjusted budget EBITDA of TDKK -20,300 · Result of

Gradientech: Interim report 1 January – 30 June 2023

Gradientech AB (publ) interim report for Q2 2023 is now available on the company's website www.gradientech.se.Second quarter 2023 · Net sales amounted to SEK 1,141 thousand (4). · Net profit/loss amounted to SEK -16,837 thousand (-17,741). · Earnings per share before and after dilution were SEK -0.95 (-1.11). · Cash flow from operating activities amounted to SEK -14,399 thousand (-21,907). · Cash and cash equivalents amounted to SEK 39,535 thousand (51,821) as of June 30, 2023. · Equity amounted to SEK 35,112 thousand (60,857) as of June 30, 2023. · Within the

Half-Yearly Report January-June 2023

Continued strong growth in both enzyme and antibody business  April – June 2023 · Net sales totaled SEK 29,463 (21,093) thousand, with a growth rate of 40%. Growth is 30%, adjusted for currency effects.   · Operating profit before depreciation and amortization (EBITDA) totaled SEK 7,687 (2,109) thousand. · Operating profit (EBIT) totaled SEK 5,981 (221) thousand. · Profit for the period totaled SEK 15,219 (672) thousand. · Earnings per share totaled SEK 0.23 (0.01). · Comprehensive income for the period totaled SEK 16,843 (811) thousand. · Cash flow from operating

Zengun Group AB (publ) Interim Report January - June 2023

“In the spring, we had the good fortune to sign two new partnering agreements, with the possibility of enabling a livelier, more sustainable city.” Mick Salonen, President and CEO Second quarter •         Net turnover amounted to MSEK 693.2 (642.2) •         EBITDA totalled MSEK 28.0 (22.1), corresponding to an EBITDA margin of 4.0% (3.4) •         Earnings before tax amounted to MSEK 11.9 (7.7) •         Operating cash flow was MSEK 30.1 (outflow: 7.3) •         Orders received totalled MSEK 389.7 (424.6) •         The order book amounted to MSEK 3,178.7 (3,263.8)

Kährs Group: Interim Report April-June 2023

Stable profitability despite lower demandKährs’ net sales decreased by -28 per cent in the second quarter, primarily due to weak demand in the residential segment in Europe, affected by increasing interest rates and general high cost inflation. Profitability was maintained by a continued strong gross margin and good cost control even if both the operating profit and the operating margin are down compared to the record-setting second quarter in 2022. Second Quarter 2023 · Net sales amounted to SEK 787 million (1,094), which was a decrease of -28 per cent. Organic change was -31 per

Everysport Group (publ) publishes Interim Report for Q2 2023: Continued strong growth in subscription revenues, lower net sales due to divested padel facilities

Summary of the second quarter 2023: · Net sales SEK 37.8 million (47.3) · Adjusted EBITDA SEK 2.7 million (1.2) · EBITDA SEK 2.7 million (1.2) · Adjusted EBIT SEK -3.5 million (-10.8) · Profit after financial items SEK -10.0 million (-12.7) · Earnings per share SEK -1.65 (-2.12) Summary January - June 2023: · Net sales SEK 81.3 million (97.6) · Adjusted EBITDA SEK 7.9 million (6.8) · EBITDA SEK 7.0 million (6.8) · Adjusted EBIT SEK -7.4 million (-16.4) · Profit after financial items SEK -17.6 million (-20.1) · Earnings per share SEK -2.95 (-3.23)“

Orthex Corporation: Half-year financial report January–June 2023

Orthex Corporation, Stock exchange release, 24 August 2023 at 9.00 a.m. EESTImproved profitability despite weak demand in the Nordics This release is a summary of Orthex Corporation’s Half-year financial report for January–June 2023. The complete report is attached to this release as a pdf-file. It is also available on Orthex’s website at https://investors.orthexgroup.com/.April–June 2023 · Invoiced sales decreased by 4.3% and totalled EUR 20.6 million (21.5) · Net sales decreased by 4.1% to EUR 20.1 million (21.0) · Adjusted EBITDA was EUR 3.1 million (0.8) · Adjusted

Beyond Frames Half Year report Q2 2023

Second quarter, April 1 – June 30, 2023 · Sales amounted to 43,291 (4,571) kSEK, an increase of 847% compared to Q2 2022.                                                                · Operating profit before depreciation and amortization and shares in associated companies' earnings (EBITDA) amounted to 4,360 (-6,351) kSEK · Profit after financial items amounted to 1,265 (-7,933) kSEK · EBITDA per share amounted to 0.25 (-0.37) SEK · Profit per share after financial items amounted to SEK 0.07 (-0.46) SEK · Cash and cash equivalents at the end of the quarter amounted to

STRONG SECOND QUARTER WITH SOLID MARGIN GROWTH

STOCKHOLM – August 24, 2023 – ContextVision, a medical technology software company renowned for its expertise in image processing, continues to achieve strong revenue figures to date, accompanied by a substantial increase in EBITDA performance."Our impressive performance was fuelled by the excellent licensing sales in our core business and boosted by favourable foreign exchange rates. We anticipate our margins to remain stable, consistently reaching a high level of 40 in the foreseeable future", says Gerald Pötzsch, CEO of ContextVision. In the second quarter, net sales amounted to SEK

Ranplan Group AB – Interim Report Jan - Jun 2023

2023-08-24 08:00 CET The period in summary First half of 2023 (first half of 2022) · Total income amounted to SEK 11.6 million (13.8 million)1 · Net sales amounted to SEK 6.2 million (8.0 million) · Operating income amounted to SEK -14.2 million (-13.7 million) · Net income amounted to SEK -15.5 million (-13.7 million) · Earnings per share amounted to SEK -0.51 (-0.45) · Cash flow from operations amounted to -SEK 10.7 million (-13.5 million) · Cash at the end of the period amounted to SEK 11.6 million (3.9 million) Significant events in the first half of 2023

Cell Impact Q2 2023: Temporary lower level of activity and cost reduction program

Cell Impact AB (Nasdaq First North GM: CI) reports the following summary for the second quarter 2023.Net sales during the second quarter totaled SEK 17.2 million (20.4). The operating profit, which dropped to –27.1 MSEK (–21.8), is disappointing and contrary to previously expected development. Before the second quarter, we saw indications of significantly increased demand during the second half-year and we expected a good full year. Instead, we received indications that involve delays in orders. Against this backdrop, in July, we announced a cost reduction program to adapt our

Zwipe H1 2023 Report – first Zwipe Pay commercial launches

OSLO, NORWAY – 24 August 2023 – Zwipe AS ("Zwipe" or "the company") today announces its results for the first half of 2023. Significant events H1 2023 · Zwipe successfully completes rights issue raising approximately 100.1 million NOK in new capital. · Zwipe and Kuwait International Bank (“KIB”) announce the first commercial launch of biometric payment cards to KIB’s Visa Infinite clients. · Middle East Payment Services (“MEPS”) announces the commercial launch of biometric payment cards from Zwipe in partnership with Mastercard. · Beautiful Card Corporation (“BCC”)

Systemair's Interim Report for the first quarter will be presented on August 31

Press Release, 24 August 2023 Systemair ABs (NASDAQ OMX Stockholm: SYSR) Interim Report Q1 for the financial year 2023/24 will be published at 13:00 CET on August 31, 2023. A telephone conference will be held at 13:30 CET on August 31, 2023. The report will be presented by Roland Kasper, CEO, and Anders Ulff, CFO.   To participate in the webcast: If you would like to participate in the webcast, please register via the link below. After registration, you will receive a link to confirm your email. There will be an opportunity to ask questions at any time during the

Implantica publishes Interim Report January – June 2023 (Q2)

RefluxStop™ Gaining Significant Traction Across Europe to Battle Acid RefluxSignificant events in the second quarter of 2023 · We launched in Italy with four new centers performing RefluxStop™ procedures, all centers of excellence, located in Napoli, Milan and the Puglia region, with leading anti-reflux surgeons. Among those is Professor Bonavina, the president of the European Foregut Society.  · The 100th RefluxStop procedure was completed in a single center at Klinikum Friedrichshafen, a leading anti-reflux Center of Excellence in Germany. · Dr. med. Borbély from InselSpital,

There are no items matching the current filter
There are no more items matching the current filter
Back to top